Back to top

Buy Rating Reaffirmed on Growing Nomlabofusp Confidence; $25 Price Target Maintained

Analyst Francois Brisebois from LifeSci Capital maintained a Buy rating on Larimar Therapeutics and keeping the price target at $25.00. Francois Br...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Larimar Therapeutics, Inc. (LRMR)